MAPT and type 2 diabetes mellitus: Metformin, a biguanide used as an oral therapy for T2DM, has been shown in in vitro animal studies to increase Aβ clearance and reduce tau phosphorylation when given at doses significantly lower than used to treat type 2 diabetes mellitus.